Skip to main content
. 2018 May 9;293(25):9801–9811. doi: 10.1074/jbc.RA117.001384

Figure 7.

Figure 7.

DLX3 inhibits PGF expression through inhibition of CBP-mediated GCM1 acetylation and activation. A and B, DLX3 inhibits the TAD activity of GCM1. 293T cells were transfected with p(GBS)4-E1bLuc, pVP16, pVP16-GCM1(1–167), and increasing amounts of pDLX3-FLAG to assess the effect of DLX3 on the DBD activity of GCM1 (A). In a different experimental setting, 293T cells were transfected with pG5-Luc, pGal4-VP16, pGal4-GCM1(167–436), and increasing amounts of pDLX3-FLAG to assess the effect of DLX3 on the TAD activity of GCM1 (B). Cells were harvested for luciferase assays at 48 h post-transfection. C, DLX3 negatively regulates FSK-stimulated PGF gene expression. BeWo cells stably expressing scrambled or DLX3 shRNA were treated with or without 50 μm FSK for 24 h and then subjected to qRT-PCR analysis of DLX3, GCM1, PGF, and hCGβ transcript levels. D, suppression of CBP-mediated GCM1 acetylation by DLX3. 293T cells were transfected with pGCM1-Myc, pCBP-FLAG, and increasing amounts of pHA-DLX3. At 48 h post-transfection, cells were harvested for coimmunoprecipitation analysis with Myc, FLAG, HA, and Ac-Lys mAbs. Error bars in A–C represent S.D. of the mean of three independent experiments. IP, immunoprecipitation; IB, immunoblotting.